BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36203122)

  • 1. Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
    Wong Chong E; Joncas FH; Seidah NG; Calon F; Diorio C; Gangloff A
    BMC Cancer; 2022 Oct; 22(1):1049. PubMed ID: 36203122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary.
    Wong Chong E; Joncas FH; Douville P; Bachvarov D; Diorio C; Calon F; Bergeron AC; Blais J; Leung SOA; Seidah NG; Gangloff A
    Lipids Health Dis; 2024 Feb; 23(1):59. PubMed ID: 38414008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.
    Fazio S; Minnier J; Shapiro MD; Tsimikas S; Tarugi P; Averna MR; Arca M; Tavori H
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3340-3348. PubMed ID: 28633452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
    Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
    Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses.
    Bouzoni E; Perakakis N; Connelly MA; Angelidi AM; Pilitsi E; Farr O; Stefanakis K; Mantzoros CS
    Metabolism; 2022 Sep; 134():155265. PubMed ID: 35820631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
    Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
    Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population.
    Hamamura H; Adachi H; Enomoto M; Fukami A; Nakamura S; Nohara Y; Morikawa N; Sakaue A; Toyomasu K; Yamamoto M; Fukumoto Y
    J Atheroscler Thromb; 2021 Apr; 28(4):329-337. PubMed ID: 32624555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Silencing of Angiopoietin-like 3 (ANGPTL3) Induced De Novo Lipogenesis and Lipid Accumulation in Huh7 Cell Line.
    Rossi I; Marodin G; Lupo MG; Adorni MP; Papotti B; Dall'Acqua S; Ferri N
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Association With Lipoprotein(a).
    Tavori H; Christian D; Minnier J; Plubell D; Shapiro MD; Yeang C; Giunzioni I; Croyal M; Duell PB; Lambert G; Tsimikas S; Fazio S
    Circ Res; 2016 Jun; 119(1):29-35. PubMed ID: 27121620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity.
    Kraaijenhof JM; Tromp TR; Nurmohamed NS; Reeskamp LF; Langenkamp M; Levels JHM; Boekholdt SM; Wareham NJ; Hoekstra M; Stroes ESG; Hovingh GK; Grefhorst A
    J Am Heart Assoc; 2023 Nov; 12(21):e030476. PubMed ID: 37889183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
    Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
    Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANGPTL3 and ANGPTL8 in Thai subjects with hyperalphalipoproteinemia and severe hypertriglyceridemia.
    Kaewkrasaesin C; Chatchomchuan W; Muanpetch S; Khovidhunkit W
    J Clin Lipidol; 2021; 15(5):752-759. PubMed ID: 34535418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ANGPTL3 is a novel HDL component that regulates HDL function.
    Yang L; Wang Y; Xu Y; Li K; Yin R; Zhang L; Wang D; Wei L; Lang J; Cheng Y; Wang L; Ke J; Zhao D
    J Transl Med; 2024 Mar; 22(1):263. PubMed ID: 38462608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.